ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Outcomes of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Diabetic Kidney Transplant Recipients

T. S. Mahmoud1, J. Yagan1, A. Hasan2, O. Gheith1, M. Mostafa1, S. Rida1, N. El-Serwy1, M. Shaker1, M. Khalid1, P. Nair1, T. Alotaibi1

1Nephrology, Organ Transplant Center, Kuwait, Kuwait, 2Immunometabolism, Dasman Diabetes Center, Kuwait, Kuwait

Meeting: 2022 American Transplant Congress

Abstract number: 29

Keywords: Hyperglycemia, Kidney transplantation, Metabolic complications, Outcome

Topic: Clinical Science » Kidney » 35 - Kidney: Cardiovascular and Metabolic Complications

Session Information

Session Name: Kidney: Cardiovascular and Metabolic Complications I

Session Type: Rapid Fire Oral Abstract

Date: Sunday, June 5, 2022

Session Time: 3:30pm-5:00pm

 Presentation Time: 4:30pm-4:40pm

Location: Hynes Veterans Auditorium

*Purpose: The impact of the new glucose lowering therapies, sodium-glucose cotransporter 2 inhibitors (SGLT2i) and Glucagon-like peptide-1 receptor agonists (GLP-1RA), on managing patients with type II diabetes mellitus is very impressive with clear evidence of improving the cardiovascular and renal outcomes. Kidney transplant recipients (KTRs) with diabetes mellites have higher risks for cardiovascular and renal morbidities and mortalities. The use of these drugs was limited by the postulated fear of their side effects on renal graft outcomes. Few case series and small prospective trials in KTRs were published in the literature. We retrospectively assessed the safety and short-term outcomes of these drugs in our patients.

*Methods: We collected data from records of 98 diabetic KTRs who received SGLT2I and another 41 who received GLP-1RA for at least 3 months. We compared them to a matched group of 70 diabetic KTRs on standard of care (SOC) therapy. Patients were at least 3 months post-transplant with stable renal function at the time of inclusion and estimated glomerular filtration rate (eGFR) of at least 25 ml/min/1.73m2. The groups were matching regarding age, gender, body mass index (BMI), type of donor, immunosuppression, post-transplant duration and type of diabetes. HbA1c was higher in both study groups compared to control (8.0% versus 7.2%). Follow up data for one year was recorded.

*Results: HbA1c dropped by 0.4% in both SGLT2i (p=0.0001) and GLP-1RA (p=0.0003) groups compared to a reduction by only 0.05% in the control group. BMI was reduced by 0.32 in SGLT2i group (p=0.0450) and by 0.34 in GLP-1RA group (p=0.0105) while increased by 0.015 in the control group. There was a tendency for better estimated glomerular filtration rate (eGFR) towards the end of the year in both study groups though it was not statistically significant except for the group of KTRs on SGLT2i with eGFR more than 90 ml/min (p=0.0135). A dip in eGFR was observed in KTRs on SGLT2i at one and 3 months. Albuminuria was significantly reduced at 12 months in SGLT2i group by a median of 28 mg/mmol of creatinine (p=0.0095) and by 20 mg/mmol creatinine in GLP-1RA group (p=0.0072) compared to increase by 3.4 mg/mmol creatinine in the control group. Side effects of the drugs were minimal and comparable to the control group.

*Conclusions: Use of SGLT2i and GLP-1RA is safe in diabetic kidney transplant recipients and is associated with better outcome with no increased side effects. Conducting randomized trials is extremely required to confirm these findings and establish the guidelines.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Mahmoud TS, Yagan J, Hasan A, Gheith O, Mostafa M, Rida S, El-Serwy N, Shaker M, Khalid M, Nair P, Alotaibi T. Outcomes of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Diabetic Kidney Transplant Recipients [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/outcomes-of-sodium-glucose-cotransporter-2-inhibitors-and-glucagon-like-peptide-1-receptor-agonists-in-diabetic-kidney-transplant-recipients/. Accessed May 9, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences